Letter to the Editor
Sir: Clozapine continues to be the gold standard for patientswith treatment-refractory schizophrenia.1 However, when patientswho have responded to clozapine need to have clozapinetreatment discontinued due to a serious adverse event, such asglucose abnormalities, clinicians are often confronted with difficult choices regarding a suitable substitute treatment.
We present a patient who developed acute ketoacidosis while on clozapine treatment and who developed severe agitationand psychotic decompensation with subsequent aripiprazole treatment.
Save
Cite
Advertisement
GAM ID: sidebar-top